NasdaqCM:CYRX

Stock Analysis Report

Executive Summary

Cryoport, Inc. provides temperature controlled logistics solutions to the life sciences industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.


Snowflake Analysis

Excellent balance sheet with high growth potential.


Similar Companies

Share Price & News

How has Cryoport's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CYRX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

6.2%

CYRX

18.0%

US Medical Equipment

12.5%

US Market


1 Year Return

18.5%

CYRX

-8.0%

US Medical Equipment

-12.7%

US Market

Return vs Industry: CYRX exceeded the US Medical Equipment industry which returned -8% over the past year.

Return vs Market: CYRX exceeded the US Market which returned -12.7% over the past year.


Shareholder returns

CYRXIndustryMarket
7 Day6.2%18.0%12.5%
30 Day-9.3%-10.6%-14.7%
90 Day-8.0%-18.2%-21.5%
1 Year18.5%18.5%-7.2%-8.0%-10.9%-12.7%
3 Year547.4%547.4%41.2%37.4%12.6%5.4%
5 Year73.7%73.7%72.5%54.7%31.9%17.5%

Price Volatility Vs. Market

How volatile is Cryoport's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Cryoport undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: CYRX ($15.15) is trading below our estimate of fair value ($31.15)

Significantly Below Fair Value: CYRX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: CYRX is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: CYRX is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYRX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYRX is overvalued based on its PB Ratio (4.5x) compared to the US Medical Equipment industry average (2.9x).


Next Steps

Future Growth

How is Cryoport forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?

96.2%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).

Earnings vs Market: CYRX is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: CYRX's is expected to become profitable in the next 3 years.

Revenue vs Market: CYRX's revenue (23.7% per year) is forecast to grow faster than the US market (7.3% per year).

High Growth Revenue: CYRX's revenue (23.7% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: CYRX's Return on Equity is forecast to be low in 3 years time (9.1%).


Next Steps

Past Performance

How has Cryoport performed over the past 5 years?

1.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYRX is currently unprofitable.

Growing Profit Margin: CYRX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYRX is unprofitable, but has reduced losses over the past 5 years at a rate of 1.8% per year.

Accelerating Growth: Unable to compare CYRX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYRX is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).


Return on Equity

High ROE: CYRX has a negative Return on Equity (-14.52%), as it is currently unprofitable.


Next Steps

Financial Health

How is Cryoport's financial position?


Financial Position Analysis

Short Term Liabilities: CYRX's short term assets ($103.0M) exceed its short term liabilities ($5.5M).

Long Term Liabilities: CYRX's short term assets ($103.0M) exceed its long term liabilities ($4.1M).


Debt to Equity History and Analysis

Debt Level: CYRX is debt free.

Reducing Debt: CYRX currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: CYRX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CYRX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYRX has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if CYRX has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Cryoport's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CYRX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYRX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYRX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

5.2yrs

Average management tenure


CEO

Jerrell Shelton (74yo)

7.33s

Tenure

US$3,839,464

Compensation

Mr. Jerrell W. Shelton, also known as Jerry, has been the Chief Executive Officer and President of CryoPort, Inc. since November 5, 2012 and has been its Chairman of the Board since October 2015. Mr. Shelt ...


CEO Compensation Analysis

Compensation vs Market: Jerrell's total compensation ($USD3.84M) is above average for companies of similar size in the US market ($USD2.17M).

Compensation vs Earnings: Jerrell's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Jerrell Shelton
Chairman7.33yrsUS$3.84m0.83% $4.7m
Robert Stefanovich
CFO, Treasurer & Corporate Secretary8.75yrsUS$1.11m0.0027% $15.2k
Phil Wilson
Senior Vice President of Global Operations & Supply Chain1.17yrsno datano data
Bret Bollinger
Chief Technology Officer2.5yrsUS$174.52kno data
Thomas Heinzen
Vice President of Corporate Development & Investor Relationsno datano datano data
Mark Sawicki
Chief Commercial Officer5.17yrsno datano data
Raymond Takahashi
Executive Officerno datano datano data
David Petreccia
Executive Officerno datano datano data

5.2yrs

Average Tenure

54yo

Average Age

Experienced Management: CYRX's management team is seasoned and experienced (5.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Jerrell Shelton
Chairman7.33yrsUS$3.84m0.83% $4.7m
Richard Berman
Lead Director4.33yrsUS$411.41k0.022% $123.3k
William Taaffe
Member of Commercial Advisory Board7.17yrsno datano data
Edward Zecchini
Independent Director6.5yrsUS$381.41k0.090% $511.3k
Robert Hariri
Independent Director4.5yrsUS$390.41k0.041% $231.8k
Rick Kriss
Member of Advisory Board12.17yrsno datano data
Larry O'Toole
Member of Advisory Boardno datano datano data
Ramkumar Mandalam
Independent Director5.75yrsUS$376.41k0.083% $471.9k
Daniel Hancock
Independent Director1.17yrsUS$837.66k0.0074% $42.4k

5.1yrs

Average Tenure

69yo

Average Age

Experienced Board: CYRX's board of directors are considered experienced (5.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: CYRX insiders have only sold shares in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.4%.


Top Shareholders

Company Information

Cryoport, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Cryoport, Inc.
  • Ticker: CYRX
  • Exchange: NasdaqCM
  • Founded: 1999
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$570.320m
  • Shares outstanding: 37.64m
  • Website: https://www.cryoport.com

Number of Employees


Location

  • Cryoport, Inc.
  • 17305 Daimler Street
  • Irvine
  • California
  • 92614
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CYRXNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2005

Biography

Cryoport, Inc. provides temperature controlled logistics solutions to the life sciences industry in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoportal, a cloud-based logistics management platform that supports the management of shipments, which includes order entry, document preparation, customs documentation, courier management, real-time shipment tracking, issue resolution, and regulatory compliance requirements; and CryoPort Express Shippers, a dry vapor cryogenic shipper that use liquid nitrogen contained inside a vacuum insulated vessel, which serves as a refrigerant to provide stable storage temperatures. It also provides Cryoport Express Dry Vapor Shippers, which are re-usable dry vapor liquid nitrogen storage containers for holding the biological material in the inner chamber; and Cryoport Express C3 Shippers designed to maintain a controlled temperature. In addition, the company offers Cryoport Express SmartPak II Condition Monitoring System to track the key aspects of each shipment; and Cryoport Express Analytics to track the time-based metrics for order processing time and on-time deliveries, as well as profiling shipping lanes to determine average transit times and predicting shipping exceptions based on historical metric. Cryoport, Inc. was founded in 1999 and is headquartered in Irvine, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/03/30 01:24
End of Day Share Price2020/03/27 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.